Insider Buying Spurs Interest in Zivo Bioscience’s Algae‑Derived Technology
On April 17, 2026, Strome Mezzanine Fund II, LP—controlled by Mark E. Strome, President of Strome Group, Inc.—purchased 100 000 shares of Zivo Bioscience at $2.00 each. The transaction, filed under Form 4, increased Strome’s stake to 572 942 shares, or roughly 12.6 % of the outstanding equity. The trade occurred when the stock was trading near $1.20, a modest 0.03 % uptick, but the buy was accompanied by a 15‑point social‑media sentiment lift and an 82 % buzz rate—an unusual confluence that signals heightened investor curiosity.
What the Move Means for Investors
The buy adds weight to an already active insider‑purchase cycle. Over the past two months, insiders—including CEO John Bernard Payne and director Yaldo Laith L.—have accumulated more than 6 % of the company’s shares. Strome’s purchase, the largest single transaction by an outside investor, signals confidence that Zivo’s algae‑derived platform can unlock value despite the stock’s steep decline (–93.6 % YTD). If insiders continue to pile in, it may temper the current negative price momentum and signal an impending bottom. Conversely, a continued sell‑off could indicate that the company’s valuation has already been fully absorbed, leaving little upside for new entrants.
Strome Mark E.: A Pattern of Strategic Accumulation
Mark E. Strome’s transaction history shows a deliberate, incremental build‑up. In February, he added 20 000 shares at $9.77 and 2 000 warrants at $0.00, bringing his post‑trade holdings to 472 942 shares. The recent purchase at $2.00—substantially below the prior price—suggests he is positioning for a deep‑value play, anticipating a rebound in the company’s valuation once the market realigns with its 52‑week high of $19.65. Strome’s background as a seasoned investor in biotech and clean‑tech ventures implies he sees a strategic opportunity to deploy capital in a company that blends natural ingredients with advanced algal biotechnology.
Implications for Zivo’s Future
Zivo’s technology—focused on natural bioactive ingredients from algal cultures—places it in a niche that has gained traction amid consumer demand for sustainable personal‑care products. The company’s current valuation is weak (P/E of –0.62, market cap $4.5 M), yet its proprietary platform could become a differentiator if it secures partnerships with major consumer‑goods brands. Strome’s buying activity may bring not only capital but also credibility, potentially accelerating product development and market entry. For investors, the insider confidence signals a potential turnaround, but the stock’s historic volatility and OTC status warrant caution.
Bottom Line
Strome’s fresh injection of shares, coupled with a recent wave of insider buying, injects a dose of optimism into a company that has struggled to maintain positive momentum. For investors, the key signals are: (1) insider accumulation at discount prices, (2) a significant social‑media buzz spike, and (3) an emerging niche product line. Monitoring subsequent trades and any partnership announcements will be essential to gauge whether Zivo Bioscience can translate its unique algal technology into sustainable growth and share price appreciation.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-04-17 | STROME MARK E () | Buy | 100,000.00 | 2.00 | Common Stock |
